NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
Pediatric Metabolic Syndrome: Difficult to Define, Important to Treat
Although there is debate over the definition of metabolic syndrome in adults, the picture is even more clouded in pediatrics. Metabolic syndrome in adults is defined as having at least three of the following five…
Nonalcoholic Fatty Liver Disease: The Hepatic Complication of Metabolic Dysmetabolism
Nonalcoholic fatty liver disease (NAFLD) is the main hepatic complication of obesity, diabetes and metabolic syndrome. Its prevalence has risen dramatically since 1980, when it was a perplexing and sporadically-observed disease as first reported by…
National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk
National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk
A Personalized Approach to Risk Stratification
Clinical practice guidelines are integral to daily management of cardiovascular diseases, including hyperlipidemia. The most 2018 Multisociety Cholesterol Guidelines advocate for a more personalized approach…
Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force
Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other…
Effects of Low-Carbohydrate and Very-Low-Carbohydrate Diets (Including Ketogenic) – Cardiometabolic Impact
Statin Use in Chronic Hepatitis C Infection, NAFLD/NASH, Cirrhosis and Hepatocellular Carcinoma
Case Presentation: G.S. is a 60-year-old male referred for cholesterol treatment complicated by background liver disease. He has a history of schizophrenia and chronic hepatitis C virus (HCV) diagnosed in 2016. He is asymptomatic and…